Tourmaline Bio, Inc.
TRML
$23.31
$0.251.08%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 22.68M | 22.58M | 22.75M | 24.36M | 22.13M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 102.45M | 98.45M | 89.73M | 78.82M | 61.02M |
Operating Income | -102.45M | -98.45M | -89.73M | -78.82M | -61.02M |
Income Before Tax | -88.47M | -82.87M | -73.21M | -63.88M | -49.29M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -88.47 | -82.87 | -73.21 | -63.88 | -49.29 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -88.47M | -82.87M | -73.21M | -63.88M | -49.29M |
EBIT | -102.45M | -98.45M | -89.73M | -78.82M | -61.02M |
EBITDA | -102.41M | -98.41M | -89.69M | -78.78M | -60.98M |
EPS Basic | -3.44 | -3.22 | -2.88 | -2.82 | -7.20 |
Normalized Basic EPS | -2.33 | -2.20 | -1.98 | -1.78 | -4.52 |
EPS Diluted | -3.44 | -3.22 | -2.88 | -2.82 | -7.20 |
Normalized Diluted EPS | -2.33 | -2.20 | -1.98 | -1.78 | -4.52 |
Average Basic Shares Outstanding | 103.01M | 102.98M | 101.37M | 91.58M | 66.89M |
Average Diluted Shares Outstanding | 103.01M | 102.98M | 101.37M | 91.58M | 66.89M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |